Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

• click to rate

  Posted by Two Blokes Apr 30 - Filed in Stock - 0 views
  
  SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.